President Donald Trump has nominated Dr. Heidi Overton, the White House Domestic Policy Deputy Director, as FDA Commissioner. Overton brings a documented record of anti-abortion activism to the role, having publicly celebrated the Supreme Court's 2022 decision overturning Roe v. Wade.
The nomination has drawn immediate criticism from reproductive rights advocates. Reproductive Freedom for All, an abortion access organization, has condemned the selection, noting that Overton's record poses a direct threat to FDA authority over medication abortion and contraception access.
The FDA's regulatory scope extends to approving and overseeing medications central to reproductive healthcare. The agency previously approved mifepristone, the primary drug used in medication abortion, and maintains oversight of birth control availability and safety. An FDA Commissioner with a documented anti-abortion record could reshape how the agency approaches these decisions.
Overton's prior statements celebrating the Dobbs decision that eliminated the federal abortion right signal her ideological orientation on reproductive policy. Her appointment would place a vocal abortion opponent in charge of the agency responsible for regulating medication abortion nationwide, at a moment when abortion access remains politically fractured across states.
The nomination reflects Trump's broader effort to reshape federal agencies with officials aligned with his administration's conservative priorities. The FDA Commissioner role requires Senate confirmation, providing a venue for Democrats and reproductive rights advocates to challenge Overton's appointment during hearings.
This move aligns with Trump's stated commitment to restrict abortion access. It comes as numerous states have already implemented near-total abortion bans following the Dobbs decision, and as medication abortion has become increasingly central to abortion access in the remaining states where the procedure remains legal.
Reproductive rights groups have signaled they will mobilize against Overton's confirmation, framing the nomination as part of a broader effort to restrict access to essential reproductive healthcare through federal regulatory action rather than legislation.